97% achieved an end-of-treatment response and 90% achieved SVR12.[32] Sofosbuvir-Based Treatment in Phase 3 Trials : In a pooled analysis of data from phase 3 trials using sofosbuvir-based regimens, investigators compared HCV treatment responses in participants receiving opioid substitution therapy during treatment (n = 194) with participants not receiving opioid substitution therapy (n = 4,549).[27] There were no significant differences in SVR12 rates (94% in those receiving opioid substitution therapy versus 97% for those not receiving opioid substitution therapy).[27] Sofosbuvir-Velpatasvir (SIMPLIFY) : In this single-arm, open-label, phase 4 study, 103 participants with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection and recent (within 6 months) injection drug use were treated with a 12-week course of sofosbuvir-velpatasvir.[22] During the treatment course, 59% (61 of 103) participants were receiving opioid substitution therapy, and 74% (76 of 103) had used injection drugs in the month prior to starting treatment.[22] A total of 97% (100 of 103) participants completed treatment

RMID:Image ID:2YADT0E Image details Contributor: Bill Waterson Image ID: 2YADT0E File size: 22.9 MB (464.3 KB Compressed download) Releases: Model - no | Property - noDo I need a release
Taste What do all these numbers add up to
This guide delves into how these machines can transform your business, ensuring compliance while maximizing convenience and profit
Corset Mauve Superslim Cigarettes by KT International